GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advicenne SA (XPAR:ALDVI) » Definitions » Total Receivables

Advicenne (XPAR:ALDVI) Total Receivables : €1.56 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Advicenne Total Receivables?

Advicenne's Total Receivables for the quarter that ended in Dec. 2023 was €1.56 Mil.


Advicenne Total Receivables Historical Data

The historical data trend for Advicenne's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advicenne Total Receivables Chart

Advicenne Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.82 0.80 1.09 1.56

Advicenne Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 1.07 1.09 1.38 1.56

Advicenne Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Advicenne Total Receivables Related Terms

Thank you for viewing the detailed overview of Advicenne's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Advicenne (XPAR:ALDVI) Business Description

Traded in Other Exchanges
Address
2, rue Briconnet, Nimes, FRA, F-30 000
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.

Advicenne (XPAR:ALDVI) Headlines

No Headlines